The FDA approved Cabozantinib for use in patients with liver cancer, Medscape reports. The drug was already approved for thyroid and renal cancer patients.
What you should know:
1. Cabozantinib can now be used in patients with hepatocellular carcinoma who were previously treated with sorafenib.
2. Cabozantinib is an orally-delivered drug which inhibits multiple receptors involved in cell function.
3. The FDA first approved the drug in 2012 as a treatment for thyroid cancer. The FDA approved the drug as a renal cancer treatment in 2016.
4. The FDA approved the drug for liver cancer patients based on a phase 3 study. In the study, patients treated with Cabozantinib saw their median survival rate increase 2.2 months.